A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1013

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Primary Progressive

Interventions

DRUG: Ocrelizumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche